Webinar: Peptide Microarrays for Cancer Research
PEPperPRINT
PEPperPRINT News


by Jill Roughan, PhD, US Business Development PEPperPRINT GmbH

Thursday, November 2, 2017 from 9:00-10:00 AM PST / 5:00-6:00 PM CET


PEPperPRINT´s unique peptide microarrays are synthesized in situ by digital laser printing directly onto glass slides. The benefits of this technique are an unlimited flexibility in terms of peptide content, excellent signal-to-noise ratios and high spot density allowing proteome-wide epitope mappings with minimal sample need.

PEPperPRINT recently developed a number of solutions for cancer research that include


To learn more about PEPperPRINT's peptide microarray solutions for cancer research including case studies and scientific publications, we invite you to join our upcoming scientific presentation followed by a Q&A session.

About the Presenter

Dr. Jill Roughan joined PEPperPRINT in April 2016 as technical sales representative on the West Coast, USA. For over 10 years prior, she has worked for research institutes, small start-up companies and large biotech and medical device corporations as an independent researcher, product and marketing manager. Dr. Roughan has managed small product portfolios but also large ones comprising up to 5000 products sold nationally and internationally.

Prior to her time at The Scripps Research Institute studying B cell responses in HIV and HCV vaccine design, she received her PhD in Immunology at Tufts Medical School in Boston. She is an author of numerous peer-reviewed journal articles and received scholarships and grants fully supporting her educational and research career.
Jill Roughan, PhD, Technical Sales Representative of PEPperPRINT

Peptide Microarrays for Cancer Research:
Discover our peptide microarray solutions for cancer-related antibody screening here.

Joint Meeting of Bioscience Societies:
Meet our representative Pedro Simonini from November 13-15th in Buenos Aires!

How to get in touch with us?
Simply select one of our offices closest to you and leave a message here.